Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion CorpfiledCriticalOrion Corp
Priority to JOP/2017/0175ApriorityCriticalpatent/JOP20170175B1/en
Publication of JOP20170175A1publicationCriticalpatent/JOP20170175A1/en
Application grantedgrantedCritical
Publication of JOP20170175B1publicationCriticalpatent/JOP20170175B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The present invention relates to an improved process for the preparation of carboxamide structured androgen receptor (AR) antagonists such as N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyandnot;ethyl)-1H-pyrazole-3-carboxamide (1A) and key intermediates thereof such as 2-chloro-4-(1H-pyrazol-3-yl)benzonitrile (V). AR antagonists are useful in the treatment of cancer, particularly prostate cancer and other diseases where AR antagonism is desired.
JOP/2017/0175A2017-10-102017-10-10Process for the preparation of androgen receptor antagonists and intermediates thereof
JOP20170175B1
(en)
1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
Compounds derived from carboxamide and urea comprising aromatic substituted pyrazole, vanilloid receptor binders; pharmaceutical composition that includes them; and its use in the treatment and / or prophylaxis of pain, migraine, parkinson's disease, gastrointestinal disorders, osteoporosis, among other diseases.
(s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrroli dine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl )acrylamide for the treatment of cancer.
1- (4- (ISOXAZOL-5-YL) -1H-PYRAZOL-1-YL) -2-METHYLPROPAN-2-OL AND SIMILAR COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITERUS FOR THE TREATMENT OF DISEASES AUTOIMMUNE AND CHRONIC INFLAMMATION
Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1 -yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof.
Pharmaceutical composition including 5-{4-(aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2h)-furanone and capsule formulation including the pharmaceutical composition
Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s